礼来宣布替尔泊肽注射液多剂量预装笔在中国正式上市 金十数据6月13日讯，礼来宣布穆峰达®（替尔泊肽注射液多剂量预装笔）在中国正式上市。替尔泊肽 注射液多剂量预装笔覆盖适应症为在饮食控制和运动基础上，接受二甲双胍和/或磺脲类药物治疗血糖 仍控制不佳的成人2型糖尿病（简称：T2DM）患者。据介绍，穆峰达（替尔泊肽注射液）是全球首个 且目前唯一获批用于T2DM和长期体重管理的每周一次葡萄糖依赖性促胰岛素多肽（GIP）/胰高糖素样 肽-1（GLP-1）受体激动剂。 （36氪） ...

Policy Developments - The National Health Commission of China is taking measures to ensure blood supply in key areas and important time periods due to a noticeable decline in voluntary blood donations, influenced by factors such as aging population and lifestyle changes [2] - In 2024, the total blood supply in China is expected to decrease year-on-year, with a cumulative blood allocation of 3.613 million units, including 583,000 units allocated between provinces, representing a 35.1% increase [2] Drug and Medical Device Approvals - Kelun Pharmaceutical announced that its subsidiary has received drug registration approval for "Cefazolin Sodium/ Sodium Chloride Injection," which is packaged in a dual-chamber bag and is suitable for emergency treatment [4] - *ST Sailong's subsidiary has obtained a drug registration certificate for Famotidine Injection, classified as a Category A drug under the national medical insurance list, primarily used for treating upper gastrointestinal bleeding [5] Capital Market Activities - Borui Pharmaceutical plans to invest 20 million yuan to subscribe to the increased registered capital of Geek Gene Technology, acquiring a 4.1667% stake in the company [7] Industry Developments - Eli Lilly announced the launch of the multi-dose prefilled pen for Tirzepatide Injection in China, aimed at addressing the needs of the growing number of diabetes and obesity patients [9] - The adult overweight rate in China is 34.3%, with an obesity rate of 16.4%, highlighting the increasing demand for weight management treatments [9] - In the first quarter of this year, Tirzepatide contributed $6.15 billion in revenue to Eli Lilly, accounting for approximately 48% of the company's total revenue [10] - Hanyu Pharmaceutical has completed the enrollment of all subjects for the Phase III clinical trial of Semaglutide Injection for weight management, currently in the follow-up phase [11] Shareholder Actions - Nine Strong Bio's major shareholder completed a share reduction plan, reducing their holdings from 30,969,636 shares to 30,769,636 shares, a decrease from 5.30% to 5.26% of voting shares [13] - Yifeng Pharmacy's controlling shareholder plans to reduce their stake by up to 2%, amounting to no more than 24,248,336 shares [14]

20:30 美国5月PPI数据/美国至6月7日当周初请失业金人数 1. 美国三大股指期货齐跌，纳指期货跌0.51%，标普500指数期货跌0.49%，道指期货跌0.62%。 2. 欧股主要指数涨跌不一，德国DAX指数跌1.02%，英国富时100指数涨0.17%，法国CAC指数跌 0.48%，欧洲斯托克50指数跌0.77%。 3. 商务部：中美双方就落实两国元首6月5日通话重要共识和巩固日内瓦经贸会谈成果的措施框架达成原 则一致，就解决双方彼此经贸关切取得新进展。 4. 美国总统特朗普：将在未来一到两周内致函贸易伙伴，设定单边关税税率。 5. 美媒：中美达成初步协议，中国对稀土出口许可设6个月期限。 6. 欧洲央行发布《欧元的国际地位》报告：黄金超越欧元成为全球第二大储备资产。 7. 著名对冲基金经理Paul Tudor Jones：随着短期利率大幅下降，美元未来1年或跌10%。 8. 富国银行：关税压力导致美股今年破顶无望，看好大中型股。 9. 惠誉将今年全球油气行业前景下调至"恶化"，因石油需求增长低于预期及供应上升。 10. Meta从多间科技公司挖角顶尖工程师，正积极打造人工通用智能(AGI)团队。 11 ...

Group 1 - The core viewpoint of the articles highlights the launch of Eli Lilly's multi-dose prefilled pen for its GLP-1 drug Tirzepatide in China, aimed at increasing supply to meet growing patient demand [1][2] - The new multi-dose prefilled pen allows for four fixed doses, enabling a single pen to be used for a month, which is more cost-effective and environmentally friendly compared to the previous single-use version [1] - Eli Lilly's competitor, Novo Nordisk, has already adopted a multi-dose prefilled solution for its GLP-1 drug Semaglutide, indicating a competitive landscape in the GLP-1 market [1] Group 2 - Eli Lilly's latest multi-dose prefilled pen is currently imported, with no plans for domestic production announced yet [2] - In October 2024, Eli Lilly plans to invest approximately 1.5 billion RMB to upgrade its Suzhou factory's capacity to meet the demand for innovative diabetes and obesity drugs in China [2] - Both Eli Lilly and Novo Nordisk are actively competing for the global GLP-1 market, engaging in mergers and collaborations, with Novo Nordisk recently announcing a partnership with Deep Apple Therapeutics to develop therapies for cardiac metabolic diseases [2]

④ 【小鹏汽车盘前跌4.3%】小鹏汽车盘前跌4.3%。消息面上，小鹏汽车法务部发文称某自媒体违反保 密协议泄露拍摄内容，已取证并将追责。小鹏汽车指出，近期公司组织了新车型产品拍摄活动，某汽车 自媒体受邀参加拍摄后违反《项目保密协议》约定，泄露产品拍摄内容，对公司的经营带来严重干扰及 不利影响。 ⑤ 【腾讯音乐盘前涨2.8%】腾讯音乐盘前涨2.8%。消息面上，高盛指出，腾讯音乐过去数年致力拓展 长篇音频和播客领域，鉴于喜马拉雅在有声书、音频IP和播客方面的影响力，拟议收购与公司扩张策略 相符。该行对腾讯音乐评级为"买入"，目标价为15.5美元。 ⑥ 【游戏驿站盘前跌超10%】视频游戏零售公司游戏驿站盘前跌超10%，消息面上，该公司计划发行价 值17.5亿美元的可转债，这有望成为美国市场上2025年迄今最大规模的可转债供应。 ① 【三大期指齐跌】截至发稿，道指期货跌0.55%、标普500指数期货跌0.41%、纳指期货跌0.38%。 ⑦ 【礼来替尔泊肽注射液多剂量预装笔在中国上市】礼来宣布穆峰达（替尔泊肽注射液多剂量预装 笔）在中国上市。这是继年初替尔泊肽成功上市后，礼来推出的新型注射装置，以增加在中国的供应， 满 ...

Core Insights - Eli Lilly announced the launch of the multi-dose prefilled pen for Tirzepatide in China, following the successful introduction of Tirzepatide earlier this year [1] - The new injection device aims to increase supply in China and meet the demand of more patients [1] - Each pen contains four fixed doses, with one dose used per week [1]